It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
The top analyst upgrades, downgrades and other research calls from Thursday include Amazon, Barrick Gold, Boston Scientific, Chipotle Mexican Grill, Gap, Gilead Sciences, Goldcorp and Workday.
Gilead Sciences, Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have been hoping that the shares will pull…
Chris Lange The top analyst upgrades, downgrades and other research calls from Monday include Best Buy, Equifax, Gilead Sciences, MongoDB, NVIDIA, Rio Tinto, Teva Pharmaceutical and UPS.
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Out of all the biotechs that reported earnings last week, Gilead Sciences seems to be the one that hasn’t been taking its medicine in 2017.
Chris Lange Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings, and…
Jon C. Ogg The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some buzz for Gilead.
Jon C. Ogg Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past is not possible. That has been the case of Gilead Sciences since…
Jon C. Ogg The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.
The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and Western Digital.
The top analyst upgrades, downgrades and other research calls from Wednesday include Freeport-McMoran, Gilead Sciences, FuelCell, Oracle, Take-Two Interactive, Tesla and Waste Management.
